[(-)-Epigallocatechin-3-gallate reduces vascular endothelial growth factor expression in gastric cancer cells via suppressing activity]
- PMID: 21866460
[(-)-Epigallocatechin-3-gallate reduces vascular endothelial growth factor expression in gastric cancer cells via suppressing activity]
Abstract
Objective: To investigate the molecular mechanism involved in the downregulation of vascular endothelial growth factor(VEGF) expression through the suppression of signal transducer and activator of transcription 3(Stat3) by(-)-Epigallocatechin-3-gallate (EGCG).
Methods: After human gastric cancer cells (AGS) were treated with IL-6 (50 μg/L) and EGCG(0, 5, 10, 25 or 50 μmol/L), the expression levels of VEGF, total Stat3(tStat3), and activated Stat3(pStat3) in tumor cells were examined by Western blotting. The influence of the inhibitor of Stat3 pathway on the IL-6-induced VEGF expression was investigated. VEGF protein level in tumor cell culture medium was determined by ELISA and VEGF mRNA expression in tumor cells by RT-PCR. Tumor cell nuclear extract was prepared and nuclear expression of pStat3 was detected. Stat3-DNA binding activity was examined with chromatin immunoprecipitation (ChIP) assay.
Results: IL-6 significantly increased VEGF expression in AGS gastric cancer cells. Compared with the group without IL-6, the expression and secretion of VEGF protein, and mRNA expression increased by 2.4 fold,2.8 fold, and 3.1 fold(all P<0.01), respectively. EGCG treatment markedly reduced VEGF protein, release and mRNA expression in a dose-dependent manner. When compared with the control group induced by IL-6, EGCG and AG490(a Stat3 pathway inhibitor) significantly inhibited VEGF expression induced by IL-6 (P<0.01). EGCG dose-dependently inhibited pStat3 induced by IL-6(P<0.05), but not tStat3 (P>0.05). Stat3 nuclear translocation and Stat3-DNA binding activity in AGS cells or that induced by IL-6 were directly inhibited by EGCG(P<0.05).
Conclusion: EGCG reduces expression of VEGF in gastric cancer cells through the inhibition of Stat3 activity.
Similar articles
-
[Epigallocatechin-3-gallate inhibits growth and angiogenesis of gastric cancer and its molecular mechanism].Zhonghua Wei Chang Wai Ke Za Zhi. 2009 Jan;12(1):82-5. Zhonghua Wei Chang Wai Ke Za Zhi. 2009. PMID: 19145512 Chinese.
-
(-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer.World J Gastroenterol. 2011 May 14;17(18):2315-25. doi: 10.3748/wjg.v17.i18.2315. World J Gastroenterol. 2011. PMID: 21633597 Free PMC article.
-
(-)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1α.Cancer Chemother Pharmacol. 2013 Mar;71(3):713-25. doi: 10.1007/s00280-012-2063-z. Epub 2013 Jan 6. Cancer Chemother Pharmacol. 2013. PMID: 23292117
-
(-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis.World J Gastroenterol. 2007 Feb 28;13(8):1162-9. doi: 10.3748/wjg.v13.i8.1162. World J Gastroenterol. 2007. PMID: 17451194 Free PMC article.
-
Targeting STAT3 in gastric cancer.Expert Opin Ther Targets. 2012 Sep;16(9):889-901. doi: 10.1517/14728222.2012.709238. Epub 2012 Jul 26. Expert Opin Ther Targets. 2012. PMID: 22834702 Review.
Cited by
-
Reduction in promotor methylation utilizing EGCG (epigallocatechin-3-gallate) restores RXRα expression in human colon cancer cells.Oncotarget. 2016 Jun 7;7(23):35313-26. doi: 10.18632/oncotarget.9204. Oncotarget. 2016. PMID: 27167203 Free PMC article.
-
Natural Agents Used in Chemoprevention of Aerodigestive and GI Cancers.Curr Pharmacol Rep. 2016 Feb;2(1):11-20. doi: 10.1007/s40495-016-0047-0. Epub 2016 Jan 16. Curr Pharmacol Rep. 2016. PMID: 27134816 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous